Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 23, 2026 11:15 ET | Source: Siren Biotechnology, Inc.

Siren Biotechnology Announces FDA Clearance of Investigator-Initiated IND to Advance Phase 1 Study in Recurrent High-Grade Glioma

Siren Biotechnology Announces FDA Clearance of Investigator-Initiated IND to Advance Phase 1 Study in Recurrent High-Grade Glioma
March 23, 2026 11:00 ET | Source: Checkerspot

Checkerspot Announces Breakthrough, using Microalgae to Produce Palmitoleic Acid Oil at Scale, Opening a New Pathway to Omega-7s

Checkerspot announced the first microalgae-based production of high-yield palmitoleic acid (POA) oil with a study published in the Journal Fermentation.
March 23, 2026 09:25 ET | Source: Umoja Biopharma, Inc.

Umoja Biopharma Appoints Dr. Marcela Maus and Dr. Athena Countouriotis to Board of Directors

SEATTLE, March 23, 2026 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc. (Umoja), a clinical-stage biotechnology company committed to delivering innovative and potentially curative immunotherapies for...
March 23, 2026 09:00 ET | Source: Senti Biosciences, Inc.

Senti Biosciences to Present Clinical and Translational Data on SENTI-202 at the 11th Annual Innate Killer Conference

SOUTH SAN FRANCISCO, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene...
March 23, 2026 09:00 ET | Source: PharmAla Biotech

Cortexa Advances Commercialisation of MDMA Supply in Australia

PharmAla provides an update on Cortexa, its Australian joint venture with Vitura Health.
March 23, 2026 08:53 ET | Source: Novonesis (Novozymes A/S)

Trading by management and close relations of management

In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the “Market Abuse Regulation”) and commission delegated regulation (EU) 1052/2016of 8 March 2016,...
March 23, 2026 08:30 ET | Source: Vaxcyte, Inc.

Vaxcyte Completes Enrollment of OPUS-1 and OPUS-2 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults

OPUS-1 Phase 3 Study Designed to Establish a New Standard for Adult Pneumococcal Conjugate Vaccines (PCVs) Through Head-to-Head Safety, Tolerability and Immunogenicity Comparisons of VAX-31 with...
March 23, 2026 08:05 ET | Source: NKGen Biotech, Inc.

NKGen Biotech Reports Combined Phase 1 Troculeucel Data Demonstrating Dose-Responsive Cognitive Improvements and Biomarker Correlations in Alzheimer’s Disease at AD/PD 2026™

Pooled analyses in patients with moderate Alzheimer’s show dose-related cognitive benefit and signs of durability. 100% of patients remained stable or improved, with 50% improving from moderate to...
March 23, 2026 08:00 ET | Source: Reviva Pharmaceuticals

Reviva Pharmaceuticals Holdings, Inc. Announces Closing of $10 Million Public Offering

CUPERTINO, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that...
March 23, 2026 08:00 ET | Source: Theriva Biologics, Inc.

Theriva™ Biologics Announces Positive End-of-Phase 2 Meeting with U.S. FDA Regarding the Design of a Phase 3 Trial of VCN-01 in Metastatic Pancreatic Ductal Adenocarcinoma

– Successful meeting with FDA enables advancement into proposed Phase 3 clinical trial of VCN-01 in combination with gemcitabine/nab-paclitaxel for the first-line treatment of metastatic PDAC – –...